( OK let's break it down: fully fully forever vertical integration and disintegration. )
"The food ingredients business Nutrinova produces the high intensity sweetener Sunett (acesulfame K)
the preservatives Nutrinova,
potassium sorbate,
and sorbic acid,
and other food ingredients.
Major end-use markets include beverages, confections, baked goods, and dairy products.
In 2021, Celanese ranked 7th on FoodTalks' Global Top 20 Food Preservative Companies list.
Celanese is one of the world's largest producers of cellulose acetate. Acetate products are primarily used in
cigarette filters,
as well as in the production of fashion apparel and linings.
Celanese also manufactures Clarifoil cellulose acetate film that is wood pulp based and certified biodegradable and compostable in home and industrial composting conditions.
Industrial specialties, using the feedstock from acetyl intermediates, manufactures polymer and emulsions such as polyvinyl acetate emulsions, and specialty chemicals as ethylene vinyl acetate.
Major end-use markets include polyvinyl alcohol producers,
paper,
mortar and gypsum,
textiles,
paints,
coatings, and adhesives manufacturers.
Advanced engineered materials offers plastic polymers to customers in the
automotive, electronics, telecommunications, and medical industries.
Major products include engineered plastics for fuel system components (provided by Ticona, the engineering polymer business of Celanese),
conveyor belts, electronics, safety systems, emissions filtration, and fluid handling."
Celanese has a process to make ethanol from natural gas.
Celanese spun off its pharmaceutical business as Celgene in 1986.
Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs.
Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias.
The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS).
Celgene was originally a unit of Celanese. In 1986, Celanese completed the corporate spin-off of Celgene following the merger of Celanese with American Hoechst.
In December 2002, Celgene acquired Anthrogenesis, a privately held New Jersey-based biotherapeutics company and cord blood banking business,
which is developing technology for the recovery of stem cells from placental tissues
following the completion of full-term successful pregnancies.
Anthrogenesis was rebranded as Celgene Cellular Therapeutics"
Citing a market capitalization of
US$67 billion,
and stock appreciation of 107%,
Celgene was Forbes Magazine's number 2 ranked drug company of 2013.
In 2014, Celgene and OncoMed Pharmaceuticals joined a cancer stem cell therapeutic development agreement with demcizumab and five other biologics from OncoMed's pipeline.[16][17] That same year, Sutro Biopharma entered into an agreement with Celgene Corporation to discover and develop multispecific antibodies and antibody drug conjugates (ADCs).[18] This followed the December 2012 collaboration between the two companies and focused on the field of immuno-oncology.
In April 2015, Celgene announced a collaboration with AstraZeneca, worth $450 million, to study their Phase III immuno-oncology drug candidate MEDI4736.
That same month, Celgene announced it would acquire Quanticel for up to $485 million in order to enhance its cancer drug pipeline. Celgene had invested in Quanticel in April 2011.
In June 2015, Celgene announced it had licensed Lyceras RORgamma agonist portfolio for up to $105 million to develop its Phase I lead compound LYC-30937 for the treatment of inflammatory bowel disease. The licensing opportunity gave Celgene the option to acquire Lycera.
In July 2015, the company announced it would acquire Receptos for $7.2 billion in a move to strengthen the company's inflammation and immunology areas.
In May 2016, the company announced it would launch partnership with Agios Pharmaceuticals, developing metabolic immuno-oncology therapies.
In October 2016, the company acquired EngMab AG for $600 million.
In January 2017, the company announced it would acquire Delinia for $775 million, increasing the company's autoimmune disease therapy offerings.
In January 2018, Celgene announced it would acquire Impact Biomedicines for $7 billion, adding fedratinib, a kinase inhibitor with potential to treat myelofibrosis
Also in January 2018, the company announced it would acquire Juno Therapeutics for $9 billion."
Celgene (Spun off from Celanese in 1986, acquired by Bristol-Myers Squibb in 2019)
Signal Pharmaceuticals, Inc (Acq 2000)
Anthrogenesis (Acq 2002)
Pharmion Corporation (Acq 2008)
Gloucester Pharmaceuticals (Acq 2009)
Abraxis BioScience Inc (Acq 2010)
Avila Therapeutics, Inc (Acq 2012)
Quanticel (Acq 2015)
Receptos (Acq 2015)
EngMab AG (Acq 2016)
Delinia (Acq 2017)
Impact Biomedicines (Acq 2018)
Juno Therapeutics (Acq 2018)
AbVitro (Acq 2016)
RedoxTherapies (Acq 2016)
____
In 1916, the Hoechst AG was one of the co-founders of IG Farben, an advocacy group of Germany's chemicals industry to gain industrial power during and after World War I. In 1925, IG Farben turned from an advocacy group into the well-known conglomerate.
Various Hoechst facilities were bombed during the Oil Campaign of World War II.
Its managers in charge were prosecuted along with other IG Farben managers —
during the Nuremberg trials —
in the IG Farben trial
for their role in
the exploitation of enslaved laborers
and for
testing drugs
on concentration camp prisoners."
___
"The Allied oil campaign of World War II[4]: 11 pitted the RAF and the USAAF against facilities
supplying Nazi Germany
with petroleum, oil, and lubrication (POL) products.
It formed part of the immense Allied strategic bombing effort during the war.
The targets in Germany and in Axis-controlled Europe included
refineries, synthetic-fuel factories, storage depots and other POL-infrastructure."
https://en.wikipedia.org/wiki/Oil_campaign_of_World_War_II
https://en.wikipedia.org/wiki/Hoechst_AG
https://en.wikipedia.org/wiki/Celgene
https://en.wikipedia.org/wiki/Celanese
1954: Purchased by the Chicago Corporation for $55,000,000. This parent company changed its name to Champlin Refining Company in 1956.
1964: The Celanese Company purchased the company.
1970: The company was sold to Union Pacific Corporation and was kept as a wholly owned subsidiary.
1984: The Retail business of Champlin was purchased by American Petrofina, after Champlin closed the refinery.
around 1986, Union Pacific Corporation and Champlin Petroleum Company sold the Corpus Christi Refinery. The Champlin trade name was part of the deal.
Champlin's name was changed to Union Pacific Resources Company (UPRC).
During late 1990s, Union Pacific Corporation spun off the Union Pacific Resources Company.
2000: Anadarko Petroleum acquired Union Pacific Resources
https://en.wikipedia.org/wiki/H._H._Champlin_House
(Donnie Darko)
No comments:
Post a Comment